Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 4/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618954 | 0.79 | FLT3 (0.51) | DYRK3CCNT1CDK9CDK5DYRK1A | |
| SCHEMBL5413859 | 0.77 | KDM4E (0.59) | PRMT5WDR77TTKNPC1 | |
| SCHEMBL5406212 | 0.77 | PRMT5 (0.47) | PRMT5WDR77CYP11B1CYP11B2TTK | |
| SCHEMBL5401418 | 0.76 | KDM4E (0.43) | FYNPRMT5WDR77TTKNPC1 | |
| SCHEMBL5403954 | 0.75 | FLT3 (0.46) | FYNPRMT5WDR77CYP17A1TTK | |
| SCHEMBL5404863 | 0.75 | KDR (0.43) | DYRK1ADYRK1BPRMT5WDR77TTK | |
| SCHEMBL5618193 | 0.75 | PRMT5 (0.39) | PRMT5WDR77TTK | |
| SCHEMBL5618828 | 0.74 | PIK3CD (0.40) | EEDPRMT5WDR77 | |
| SCHEMBL5411363 | 0.74 | KDR (0.43) | DYRK1ADYRK1BPRMT5WDR77NPC1 | |
| SCHEMBL5406809 | 0.74 | MEN1 (0.40) | DYRK3CCNT1CDK9CDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | DYRK3 540/4885CCNT1 1539/4885CDK9 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.